A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Clinical trial NCT06158854 · RECRUITING

Trial details

NCT number: NCT06158854
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Immunoglobulin Light Chain (AL) Amyloidosis

Start date: 2024-04-01
Primary completion: 2028-02-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.